Michael Hofman, Director of Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC) at Peter MacCallum Cancer Centre, shared a post on X:
“The Lancet Oncology : PSMA-PET risk groups redefine prognosis in prostate cancer: in 11,154 patients; visual and quantitative nomograms predicted 3-, 5-, and 7-year survival. Major step for PET-based trial design, and guideline integration.”
Title: New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study
Authors: Madeleine Karpinski, Caner Civan, Isabel Rauscher, Osman Güven, Matthias Eiber, Sebastian Hoberück, Matthias Miederer, Ralph Bundschuh, Tobias Hölscher, Jeremie Calais, Lela Theusi, Andrew Nguyen, Helen Scholtissek, Constantin Lapa, Andrea Di Giorgio, Andrea Farolfi, Dominic Ufton, Alexander Drzezga, Jolanta Kunikowska, Kacper Pełka, Laura Evangelista, Glenn Bauman, Göksel Alçın, Stephan Beintner-Skawran, Mohd Fazrin Mohd Rohani, Jonathan Miksch, Anika Hüsing, Claudia Kesch, Ken Herrmann, Martin Stuschke, Lale Umutlu, Andrei Gafita, Michael Hofman, Thomas Hope, Karolien Goffin, Felix Kind, Daniele Pizzuto, Timo Soeterik, Halil Kömek, Louise Emmett, Andrej Vondrak, Tomas Pinter, Francesco Lanfranchi, Matteo Bauckneht, Lena Unterrainer, Adrien Holzgreve, Anders Bjartell, Elin Trägårdh, Sazan Rasul, Marcin Miszczyk, Martin Bögemann, Nadir Rodriguez SantAnna Jauregui, Michael Schäfers, Kambiz Rahbar, Boris Hadaschik, Wolfgang Fendler
Read the Full Article.
Other articles featuring Michael Hofman on OncoDaily.
